-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group Makes a Spectacular Appearance at the 21st China International Pharmaceutical Ingredients Exhibition.
Category:
Time：2023-06-23
On June 19, the 21st China Pharmaceutical Ingredients Exhibition (CPHI China 2023) and the 16th China Pharmaceutical Machinery, Packaging Equipment & Materials Exhibition (PMEC China 2023) kicked off with great fanfare at the Shanghai New International Expo Center (Pudong). The API Division of Shijiazhuang Sihua Pharmaceutical Group and the group’s Boshi Medical Devices’ domestic and international sales teams made a stunning debut with their new products.
On June 19, the 21st China Pharmaceutical Ingredients Exhibition (CPHI China 2023) and the 16th China Pharmaceutical Machinery, Packaging Equipment & Materials Exhibition (PMEC China 2023) kicked off with great fanfare at the Shanghai New International Expo Center (Pudong). The API Division of Shijiazhuang Sihua Pharmaceutical Group and the group’s Boshi Medical Devices’ domestic and international sales teams made a splendid appearance, showcasing their new products.
It is reported that this exhibition will last for three days, covering an exhibition area of 200,000 square meters and attracting more than 3,000 domestic and international suppliers as well as over 55,000 professional visitors and business guests from home and abroad.
At the exhibition, business visitors from both home and abroad gathered in front of Shijiazhuang No.4 Pharmaceutical’s specially designed booth to learn more and discuss business opportunities. Relevant officials and sales representatives from the group introduced to the visitors the group’s innovative development progress as well as the advantages of its featured formulations, bulk active pharmaceutical ingredients, and pharmaceutical packaging materials. “It’s been two years since we last met with Shijiazhuang No.4 Pharmaceutical Group. Seeing so many new products and such a wide variety on display is truly exciting. Shijiazhuang No.4 Pharmaceutical’s development has opened up even more opportunities for us to collaborate!” praised a Southeast Asian foreign businessman during his exchange with the group’s foreign trade staff. Throughout the exhibition, the group attracted extensive attention from industry professionals and business visitors. It held discussions and exchanges with over 200 existing and new clients, distributed more than 500 product brochures, and reached or preliminarily agreed upon about 20 business cooperation deals.
During the exhibition, relevant personnel from the Group also attended several related conferences organized by the China Medical Insurance Association, including the “12th China and World Pharmaceutical Entrepreneurs Summit” and the “2023 CPHI China and World International Regulatory Q&A Session.” At these events, they gained insights into the latest international market trends, received updates on international registration, audit, and regulatory policies, and engaged in discussions and exchanges with participating companies to explore potential future business cooperation opportunities.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has focused on operating in the international market and has taken a variety of proactive measures, including recruiting foreign trade professionals, implementing international quality certifications and audits, expanding overseas product registrations, and proactively adapting to changes in international trade regulations. As a result, the group has steadily accelerated its “going global” strategy. Its finished dosage forms are now sold in nearly 100 countries and regions worldwide, while its active pharmaceutical ingredients are highly favored in over 40 countries.
It is understood that CPHI & PMEC China has gradually evolved into an industry benchmark characterized by its core competitiveness in specialization, internationalization, and high-end positioning. To date, the exhibition has expanded to cover 15 major sub-sectors spanning the entire pharmaceutical value chain. Its exhibits encompass pharmaceutical raw materials, intermediates and fine chemicals, pharmaceutical excipients, finished dosage forms, biopharmaceuticals, packaging materials, laboratory instruments, as well as environmental protection and cleanroom technologies—fields that have garnered widespread attention and recognition from companies and professionals around the globe.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license